Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis

Table 1

Baseline demographic and clinical characteristics in study sample.

𝑁	929
Gender (% female)	75
Age (years, mean ± SD)	41±10.5
Disease duration (years, mean ± SD)	7.9±8.1
Race (% white)	95
Follow-up time (months, mean ± SD)	44.7±29.4
EDSS (mean ± SD)	1.22±1.08
Pyramidal scale (mean ± SD)	0.61±0.82
Cerebellar scale (mean ± SD)	0.28±0.66
Brainstem scale (mean ± SD)	0.15±0.43
Sensory scale (mean ± SD)	0.53±0.77
Bowel bladder scale (mean ± SD)	0.27±0.56
Mental scale (mean ± SD)	0.17±0.49
Visual scale (mean ± SD)	0.22±0.66
Treatment (% IFN, % GA, % other, % untreated)	29.7, 30.9, 7.2, 32.2

EDSS: expanded disability status scale, IFN: all forms of interferon-𝛽, GA: glatiramer acetate, other: natalizumab, rituximab, cyclophosphamide, daclizumab, mycophenolate mofetil, mitoxantrone, or combination treatment.